

Which process or biomolecule would you study with a chemical probe if you had one in hand?


Genome Wide Association Study (GWAS):

hair-related phenotypes

A genome-wide association scan in admixed Latin Americans identifies loci influencing facial and scalp hair features

Kaustubh Adhikari et al. Nature Communications, 2016


doi: 10.1038/ncomms10815.



GWAS: correlates single-nucleotide changes across the genome with specific traits

The Cancer Dependency Map

interrogation of viability effects in cancer cell lines to map genetic dependencies



Discovery of potential **TARGETS** for therapeutic discovery

Discovery of **PREDICTORS** of patient response

Pre-publication **DATA RELEASES** to enable the scientific community at depmap.org

As of 11/21/21:

>2,000 cancer models

3913 genetic dependency screens

33 drug panels in sensitivity screens

Tsherniak et al., *Cell*, 170 (3): 564-576 (2017)

McDonald et al., *Cell*, 170 (3): 577-592 (2017)

Vazquez & Boehm, *Mol Sys Bio*, 16 (7): e9757 (2020)


Dharia et al., *Nat Genet*, 53 (4): 529-538 (2021)

IRF4interferon regulatory factor 4

Overview Dependency Characterization Description

Dependent Cell Lines

CRISPR: 42/558 **STRONGLY SELECTIVE**
RNAi: 11/711 **STRONGLY SELECTIVE**



Dependency Score: Outcome from DEMETER2 or CERES. A lower score means that a gene is more likely to be dependent in a given cell line. A score of 0 is equivalent to a gene that is not essential whereas a score of -1 corresponds to the median of all common essential genes.

Strongly Selective: A gene whose dependency is at least 100 times more likely to have been sampled from a skewed distribution than a normal distribution (i.e. skewed-LRT value > 100).

[View more](#)


The protein encoded by this gene belongs to the IRF (interferon regulatory factor) family of transcription factors, characterized by an unique truntonhan pentad repeat DNA-binding domain. The IRFs are

Search external sites for IRF4

- PubMed (996 entries)
- GeneCards
- GTEX
- NCBI


Enriched Lineages

CRISPR




1. Multiple Myeloma (4.4e-79)
2. Haematopoietic And Lymphoid (3.4e-39)
3. Solid (4.5e-38)
4. Lymphoma (4.0e-15)
5. T-cell lymphoma Other (9.5e-12)
6. ALCL (9.9e-07)
7. Melanoma (1.3e-04)

RNAi




1. Multiple Myeloma (1.3e-72)
2. Haematopoietic And Lymphoid (3.3e-28)
3. Solid (6.5e-21)

Expression & CN



[View more](#)

Mutations



[View more](#)

Target Tractability



Bioactive Compounds	No
Druggable Structure	No
Druggable by Ligand Based Assessment	No
Enzyme	No

Original and additional data on *CanSAR*

[View more](#)

Top Co-dependencies


CRISPR (Avana) Public 19Q1

Gene	Pearson correlation
Plot PRDM1	0.58
Plot POU2AF1	0.57
Plot NFKB1	0.50
Plot MEF2C	0.47
Plot IKBKB	0.45

Combined RNAi (Broad, Novartis, Marcotte)


Gene	Pearson correlation
Plot NFKB1	0.35
Plot ARMCX6	0.33
Plot TLNDR1	0.32
Plot SP2	-0.31
Plot MYSM1	0.31

Our protein target - TDP-43



February 8, 2022


TDP-43



414 amino acids

TAR DNA-binding Protein that is 43 kilodaltons

How big is the typical protein?



TDP-43



insulin
5.8 kDa



trypsin
23.3 kDa




hemoglobin
64.5 kDa




hexokinase
102 kDa




immunoglobulin G
150 kDa



ATP synthase complex
>500 kDa



Domain structure of TDP-43




Four major domains

- NTD** = N-terminal domain
- RRM1** = RNA-recognition motif 1
- RRM2** = RNA-recognition motif 2
- Gly-rich** = C-terminal glycine-rich domain

50 missense mutations identified in ALS patients
(prevalent mutations in red)


multiple cleavage products

Nuclear and cytoplasmic functions of TPD-43



Amyotrophic lateral sclerosis

ALS or Lou Gehrig's disease



- progressive neurodegenerative disease that destroys motor neurons
- when motor neurons cannot send impulses to muscle, the muscles begin to waste away
- nerve cell death makes it impossible for the brain to control muscles or signal for them to move
- eventually, all muscles are affected, including arms and hands, legs and feet, and those that control swallowing and breathing

ALS stats



- 90% of ALS cases are sporadic and strike any race or ethnic background, at any age
- ALS is responsible for 2 deaths per 100,000 people (annually), greater than Huntington's or multiple sclerosis
- ~5,000 patients diagnosed each year in the US, ~30,000 at any given time
- life expectancy from diagnosis is 2-5 years, 20% live longer
- 80% cases begin between at 40-70 yo
- Gulf War veterans develop ALS at ~2x the rate of the typical population
- care costs are high (avg. >\$200k/yr)

Pete Frates, Who Promoted the Ice Bucket Challenge, Dies at 34

The former college baseball player's involvement in the viral trend helped raise more than \$100 million toward fighting A.L.S.



Pete Frates and his wife, Julie, at a Boston Red Sox game in 2015. He helped raise more than \$100 million toward fighting amyotrophic lateral sclerosis, a disease he learned he had in 2012. Elise Amendola/Associated Press

The New York Times



By Jonah Engel Bromwich

Dec. 9, 2019



By —
**Katherine
Harmon**

Leave a
comment

Share ...



How did Stephen Hawking live 55 years with ALS?

Science Jan 9, 2012 10:59 AM EST



Left: Cosmologist Stephen Hawking on October 10, 1979 in Princeton, New Jersey. Photo by Santi Visalli/Getty Images

Go Deeper

als

amyotrophic lateral
sclerosis

lou gehrig's disease

stephen hawking

died age 76



Lou Gehrig
Baseball
died 3 yr pd



Ezzard Charles
Boxer
died 8 yr pd



Dwight Clark
Football
died 3 yr pd



Mao Zedong
died of heart attack




Hideyuki Ashihara
Karate Master
died 8 yr pd



Marián Čižovský
Soccer
died 6 yr pd



Joost van der Westhuizen
Rugby
died 6 yr pd



Nobel Laureate
Harry Kroto
died 2 yr pd

Women?

'sporadic' cases – 90%, usually in 50s
2x more frequent in men than women


familial cases – 10%, younger onset
affects men and women equally

several gene mutations have been discovered in
familial disease (FALS):

hexanucleotide (GGGCCC) repeat expansion in non-coding
region of C9ORF72 gene on chromosome 9p21



SOD1 – Cu/Zn superoxide dismutase

TDP-43 – RNA processing protein that forms toxic
neuronal and glial inclusion bodies



Massive unmet therapeutic need for ALS patients



only one drug available



Riluzole


- delays the onset of ventilator-dependence
- may increase survival by 2-3 months
- 9% gain in probability of surviving 1 year
- many side effects
- interacts with sodium channels in damaged neurons
- may non-specifically interact with other receptors (kainite, NMDA, GABA_A)
- primary mechanism of action is stimulation of glutamate uptake
- glutamate lingers at synapses of damaged neurons and swift clearance is necessary

Domain structure of TDP-43




NTD region
aa 1-77
PDB ID = 2N4P

Domain structure of TDP-43





C-term
aa 311-360
PDB ID = 2N3X




Low complexity domain (LCD)
tendency to aggregate

Domain structure of TDP-43



Tandem RNA-binding motifs
aa 102-269
PDB ID = 4BS2

Domain structure of TDP-43




Maltose Binding Protein (MBP) is an *enhancer of protein solubility*


fusion protein architecture



comparison of solubility across
multiple passengers




TDP-43 purification in 20.109 lab




SNAP tags can be fused to proteins and further specifically and covalently tagged with a ligand

dye labeling reaction

engineered O-6-methylguanine-
DNA methyltransferase (MGMT)



SNAP tags can be used in many applications



October
2019

Research |  Full Access


Isolation and characterization of soluble human full-length TDP-43 associated with neurodegeneration

Mirella Vivoli Vega, Alessia Nigro, Simone Luti, Claudia Capitini, Giulia Fani, Leonardo Gonnelli, Francesca Boscaro, and Fabrizio Chiti 


Published Online: 1 Oct 2019 | <https://doi.org/10.1096/fj.201900474R>

THE FASEB JOURNAL


nickel chromatography
(denaturing conditions)




size exclusion column
(denaturing conditions)




refolding & western blot




mass spectrometry - MW & sequence



analytical SEC reveals a dimer!




N-Terminal Domain (NTD) forms homodimers in crystal structures



NTD orientation plays a role in TDP-43 polymerization and phase separation


TDP-43 oligomers:

Functional high-order oligomers promote phase separation




NTD oligomerization-disrupting mutants:

Disruption of NTD/NTD contacts destabilizes phase separation



peptidomimetics or small molecules
as a therapeutic strategy
to sequester mutants from aggregation?

RNA binding assists liquid-liquid phase separation of TDP-43 in disease



Companies are interested in **agents to control phase separation** in an effort to develop drugs for neurodegeneration and cancer

nature biotechnology

[Explore content](#) ▾ [About the journal](#) ▾ [Publish with us](#) ▾

[nature](#) > [nature biotechnology](#) > [news](#) > article

News | [Published: 09 February 2021](#)

Drug startups coalesce around condensates

[Elie Dolgin](#)


[Nature Biotechnology](#) **39**, 123–125 (2021) | [Cite this article](#)

7045 Accesses | **5** Citations | **100** Altmetric | [Metrics](#)

Once a neglected biological phenomenon, condensates are attracting interest from small companies and large pharma.

dewpoint_x





> *EMBO J.* 2022 Feb 3;e108443. doi: 10.15252/embj.2021108443. Online ahead of print.

Disease-linked TDP-43 hyperphosphorylation suppresses TDP-43 condensation and aggregation

Lara A Grujic da Silva ^{1 2}, Francesca Simonetti ^{1 2 3}, Saskia Hutten ¹, Henrick Riemenschneider ³, Erin L Sternburg ¹, Lisa M Pietrek ⁴, Jakob Gebel ⁵, Volker Dötsch ⁵, Dieter Edbauer ^{2 3 6}, Gerhard Hummer ^{4 7}, Lukas S Stelzl ^{1 4 8 9}, Dorothee Dormann ^{1 6 9}

Affiliations + expand

PMID: 35112738 DOI: 10.15252/embj.2021108443

> *PLoS One.* 2022 Feb 3;17(2):e0255710. doi: 10.1371/journal.pone.0255710. eCollection 2022.

Low-level overexpression of wild type TDP-43 causes late-onset, progressive neurodegeneration and paralysis in mice

Chunxing Yang ¹, Tao Qiao ¹, Jia Yu ², Hongyan Wang ¹, Yansu Guo ¹, Johnny Salameh ³, Jake Metterville ³, Sepideh Parsi ¹, Issa Yusuf ¹, Robert H Brown ^{3 4 5}, Huaibin Cai ², Zuoshang Xu ^{1 4 5}

Affiliations + expand

PMID: 35113871 PMCID: PMC8812852 DOI: 10.1371/journal.pone.0255710

> *Nat Neurosci.* 2022 Jan;25(1):26-38. doi: 10.1038/s41593-021-00975-6. Epub 2021 Dec 16.

TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP-43-related neurodegeneration

Manling Xie ^{# 1 2}, Yong U Liu ^{# 3 4}, Shunyi Zhao ¹, Lingxin Zhang ⁵, Dale B Bosco ¹, Yuan-Ping Pang ⁶, Jun Zhong ⁷, Udit Sheth ^{2 8}, Yuka A Martens ⁸, Na Zhao ⁸, Chia-Chen Liu ⁸, Yongxian Zhuang ⁵, Liwei Wang ⁵, Dennis W Dickson ⁸, Mark P Mattson ⁹, Guojun Bu ⁸, Long-Jun Wu ^{10 11 12}

Affiliations + expand

PMID: 34916658 PMCID: PMC8741737 (available on 2022-06-16)

DOI: 10.1038/s41593-021-00975-6

our knowledge is rapidly evolving

> *Nature.* 2022 Jan;601(7891):139-143. doi: 10.1038/s41586-021-04199-3. Epub 2021 Dec 8.

Structure of pathological TDP-43 filaments from ALS with FTL

Diana Arseni ¹, Masato Hasegawa ², Alexey G Murzin ¹, Fuyuki Kametani ², Makoto Arai ³, Mari Yoshida ⁴, Benjamin Ryskeldi-Falcon ⁵

Affiliations + expand

PMID: 34880495 PMCID: PMC7612255 (available on 2022-07-01)

DOI: 10.1038/s41586-021-04199-3

> *Neuron.* 2022 Jan 11;S0896-6273(21)01036-9. doi: 10.1016/j.neuron.2021.12.019.

Online ahead of print.

Genome-wide identification of the genetic basis of amyotrophic lateral sclerosis

Sai Zhang ¹, Johnathan Cooper-Knock ², Annika K Weimer ¹, Minyi Shi ¹, Tobias Moll ², Jack N G Marshall ², Calum Harvey ², Helia Ghahremani Nezhad ², John Franklin ², Cleide Dos Santos Souza ², Ke Ning ², Cheng Wang ³, Jingjing Li ³, Allison A Dillott ⁴, Sali Farhan ⁴, Eran Elhaik ⁵, Iris Pasnieceanu ², Matthew R Livesey ², Chen Eitan ⁶, Eran Hornstein ⁶, Kevin P Kenna ⁷, Project MinE ALS Sequencing Consortium; Jan H Veldink ⁷, Laura Ferraiuolo ², Pamela J Shaw ², Michael P Snyder ⁸

Collaborators, Affiliations + expand

PMID: 35045337 DOI: 10.1016/j.neuron.2021.12.019

> *J Med Chem.* 2022 Jan 27;65(2):1585-1607. doi: 10.1021/acs.jmedchem.1c01942.

Epub 2022 Jan 3.

TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy

Vanessa Nozal ^{1 2}, Loreto Martínez-González ^{1 2}, Marta Gomez-Almeria ³, Claudia Gonzalo-Consuegra ³, Paula Santana ⁴, Apirat Chaikuad ^{5 6}, Eva Pérez-Cuevas ^{1 2}, Stefan Knapp ^{5 6}, Daniel Lietha ¹, David Ramírez ⁷, Sabrina Petralia ⁸, Barbara Monti ⁸, Carmen Gil ¹, Angeles Martín-Requero ^{1 2}, Valle Palomo ^{1 2}, Eva de Lago ^{2 3}, Ana Martínez ^{1 2}

Affiliations + expand

PMID: 34978799 DOI: 10.1021/acs.jmedchem.1c01942

> *Brain.* 2022 Jan 25;awab285. doi: 10.1093/brain/awab285. Online ahead of print.



Phosphorylated TDP-43 aggregates in peripheral motor nerves of patients with amyotrophic lateral sclerosis

Nilo Riva ^{1 2}, Francesco Gentile ¹, Federica Cerri ^{1 2}, Francesca Gallia ³, Paola Podini ¹, Giorgia Dina ¹, Yuri Matteo Falzone ^{1 2}, Raffaella Fazio ², Christian Lunetta ⁴, Andrea Calvo ⁵, Giancarlo Loggrosino ⁶, Giuseppe Lauria ^{7 8}, Massimo Corbo ⁹, Sandro Iannaccone ¹⁰, Adriano Chiò ⁵, Alberto Lazzerini ¹¹, Eduardo Nobile-Orazio ³, Massimo Filippi ^{2 12 13 14}, Angelo Quattrini ¹

Affiliations + expand

PMID: 35076694 DOI: 10.1093/brain/awab285

TDP-43 aggregation is observed in multiple diseases



Upcoming lectures

2/3/22	Lecture 1	Intro to chemical biology: small molecules, probes, and screens
2/8/22	Lecture 2	Our protein target: TDP-43
2/10/22	Lecture 3	Small molecule microarrays
2/15/22	Lecture 4	Quantitative evaluation of protein-ligand interactions
2/17/22	Lecture 5	A ligand discovery vignette: sonic hedgehog
2/22/22	No Class	
2/24/22	Lecture 6	Engineering transcriptional responses with a small molecule
3/1/22	Lecture 7	Wrap up discussion for Mod 1 experiments and report